Abstract | BACKGROUND AND OBJECTIVES: METHODS: This is a retrospective cohort study using administrative health database information from Ontario, Canada. Prescription medication records were obtained from the Ontario Drug Benefit Claims Database. Diagnostic codes were obtained from the Ontario Health Insurance Plan Database, the Canadian Institute for Health Information Discharge Abstract Database, and the same- day surgery database. Patients who received a new prescription for domperidone between April 1, 2003 and March 31, 2010 were included. RESULTS: A total of 122,233 patients met inclusion criteria; 85 % were between 66 and 84 years old and 63 % were female. The mean estimated daily domperidone dose was 35 mg, and the estimated daily dose was <40 mg for 62 % of users. Strong or moderately strong cytochrome P-450 (CYP) 3A4 inhibitors were co-prescribed for 4.3 and 10.7 % of users, while medications with a known risk or possible risk for torsades de pointes (TdP) were co-prescribed to 18.3 and 18.8 % of users. CONCLUSIONS: Older domperidone users were commonly co-prescribed drugs with the potential to increase the risk for TdP. These combinations should be avoided, as iatrogenic QT prolongation is a modifiable risk factor for TdP.
|
Authors | Carlos Rojas-Fernandez, Anne L Stephenson, Hadas D Fischer, Xuesong Wang, Tiago Mestre, Janine R Hutson, Margarita Pondal, Douglas S Lee, Paula A Rochon, Connie Marras |
Journal | Drugs & aging
(Drugs Aging)
Vol. 31
Issue 11
Pg. 805-13
(Nov 2014)
ISSN: 1179-1969 [Electronic] New Zealand |
PMID | 25227452
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiemetics
- Cytochrome P-450 CYP3A Inhibitors
- Domperidone
|
Topics |
- Aged
- Aged, 80 and over
- Antiemetics
(administration & dosage, adverse effects, pharmacokinetics)
- Cohort Studies
- Cytochrome P-450 CYP3A Inhibitors
(administration & dosage, adverse effects, pharmacokinetics)
- Domperidone
(administration & dosage, adverse effects, pharmacokinetics)
- Drug Interactions
- Female
- Humans
- Male
- Ontario
(epidemiology)
- Practice Patterns, Physicians'
- Risk Factors
- Torsades de Pointes
(chemically induced, epidemiology, metabolism)
|